FDA
-
-
-
-
-
-
-
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patie
-
-
-
-
-
-
-
Ligand Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
-
-
-
-
-
-
-
CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
-
-
-
-
-
-
-
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
-
-
-
-
-
-
-
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
-
-
-
-
-
-
-
CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
-
333,619 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


